Inhibition of the mitochondrial protein Opa1 curtails breast cancer growth

Bibliographic Details
Title: Inhibition of the mitochondrial protein Opa1 curtails breast cancer growth
Authors: Margherita Zamberlan, Amandine Boeckx, Florian Muller, Federica Vinelli, Olivier Ek, Caterina Vianello, Emeline Coart, Keitaro Shibata, Aurélie Christian, Francesca Grespi, Marta Giacomello, Ingrid Struman, Luca Scorrano, Stéphanie Herkenne
Source: Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-18 (2022)
Publisher Information: BMC, 2022.
Publication Year: 2022
Collection: LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
More Details: Abstract Background Mitochondrial fusion and fission proteins have been nominated as druggable targets in cancer. Whether their inhibition is efficacious in triple negative breast cancer (TNBC) that almost invariably develops chemoresistance is unknown. Methods We used a combination of bioinformatics analyses of cancer genomic databases, genetic and pharmacological Optic Atrophy 1 (OPA1) inhibition, mitochondrial function and morphology measurements, micro-RNA (miRNA) profiling and formal epistatic analyses to address the role of OPA1 in TNBC proliferation, migration, and invasion in vitro and in vivo. Results We identified a signature of OPA1 upregulation in breast cancer that correlates with worse prognosis. Accordingly, OPA1 inhibition could reduce breast cancer cells proliferation, migration, and invasion in vitro and in vivo. Mechanistically, while OPA1 silencing did not reduce mitochondrial respiration, it increased levels of miRNAs of the 148/152 family known to inhibit tumor growth and invasiveness. Indeed, these miRNAs were epistatic to OPA1 in the regulation of TNBC cells growth and invasiveness. Conclusions Our data show that targeted inhibition of the mitochondrial fusion protein OPA1 curtails TNBC growth and nominate OPA1 as a druggable target in TNBC.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1756-9966
Relation: https://doaj.org/toc/1756-9966
DOI: 10.1186/s13046-022-02304-6
Access URL: https://doaj.org/article/ef5ee15a1b5a42608f6031e1dae86383
Accession Number: edsdoj.f5ee15a1b5a42608f6031e1dae86383
Database: Directory of Open Access Journals
Full text is not displayed to guests.
More Details
ISSN:17569966
DOI:10.1186/s13046-022-02304-6
Published in:Journal of Experimental & Clinical Cancer Research
Language:English